Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPSISR15] to Von Willebrand Factor
- Suitable for: Flow Cyt, WB, ICC/IF
- Reacts with: Human
Product nameAnti-Von Willebrand Factor antibody [EPSISR15]
See all Von Willebrand Factor primary antibodies
DescriptionRabbit monoclonal [EPSISR15] to Von Willebrand Factor
Tested applicationsSuitable for: Flow Cyt, WB, ICC/IFmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to residues in human Von Willebrand Factor (P04275)
- Human serum, Human plasma, HepG2 cells
Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 40% Glycerol (glycerin, glycerine), 0.05% BSA, 59% PBS
Concentration information loading...
PurityProtein A purified
Our Abpromise guarantee covers the use of ab154193 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 309 kDa.|
|ICC/IF||1/250 - 1/500.|
FunctionImportant in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
Involvement in diseaseDefects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
Sequence similaritiesContains 1 CTCK (C-terminal cystine knot-like) domain.
Contains 4 TIL (trypsin inhibitory-like) domains.
Contains 3 VWFA domains.
Contains 3 VWFC domains.
Contains 4 VWFD domains.
DomainThe von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
modificationsAll cysteine residues are involved in intrachain or interchain disulfide bonds.
N- and O-glycosylated.
Cellular localizationSecreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
- Information by UniProt
- Coagulation factor VIII antibody
- Coagulation factor VIII VWF antibody
- F8VWF antibody
Immunocytochemistry/ Immunofluorescence analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Von Willebrand Factor with Purified ab154193 at 1:250 dilution. Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor ® 594) 1:200 (2.5 μg/ml). ab150077 Goat anti rabbit IgG(Alexa Fluor ® 488) was used as the secondary antibody at 1:1000 dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193) at 4 µg/ml + HepG2 (Human hepatocellular carcinoma epithelial cell) whole cell lysate at 20 µg
Goat Anti-Rabbit IgG (HRP), specific to the non-reduced form of IgG at 1/20000 dilution
Predicted band size: 309 kDa
Exposure time: 30 seconds
Blocking and diluting buffer: 5% NFDM/TBST
The expression profile observed is consistent with the literature (PMID:24769235) in which ab154193 was validated by knockdown assay in HepG2 cell line.
Flow cytometry analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Von Willebrand Factor (red) with purified ab154193 at a 1/130 dilution (10ug/mL). Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody at a 1/2000 dilution. Black - Rabbit monoclonal IgG (Black) (ab172730). Blue (unlabeled control) - Cell without incubation with primary antibody and secondary antibody (Blue).
Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193) at 1/1000 dilution (purified) + Human plasma lysates at 15 µg
Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution
Predicted band size: 309 kDa
Observed band size: 309 kDa
Blocking and diluting buffer: 5% NFDM/TBST.
All lanes : Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193) at 1/1000 dilution (unpurified)
Lane 1 : Human serum
Lane 2 : Human plasma
Lysates/proteins at 10 µg per lane.
Predicted band size: 309 kDa
Immunofluorescent staining of HepG2 cells labeling Von-Willebrand-Factor with unpurified ab154193 at 1/250 dilution.
ab154193 has been referenced in 4 publications.
- Wang H et al. Delivery of MSCs with a Hybrid ß-Sheet Peptide Hydrogel Consisting IGF-1C Domain and D-Form Peptide for Acute Kidney Injury Therapy. Int J Nanomedicine 15:4311-4324 (2020). PubMed: 32606679
- Lu J et al. Isolation and multipotential differentiation of mesenchymal stromal cell-like progenitor cells from human bladder. Mol Med Rep N/A:N/A (2018). PubMed: 30431114
- Zhu X et al. von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage. Sci Rep 6:35901 (2016). ICC/IF ; Mouse . PubMed: 27782211
- Liu Y et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics 106:99-112 (2014). WB, IHC ; Human . PubMed: 24769235